Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00841100 · ClinicalTrials.gov registry record · Phase 2

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

A Phase 2 study, sponsored by University of Miami.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target

NCT00841100 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00841100, a Phase 2 study, has completed, sponsored by University of Miami.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target

Study Summary

The investigators will investigate the effect of blood phenylalanine on Kuvan responsiveness in the same patients with PKU when their blood phenylalanine concentrations are altered by diet. Lowering blood phenylalanine concentrations in Kuvan non-responsive patients with PKU will increase the frequency of Kuvan responsiveness.

Interventions

  • OTHER Diet
  • DRUG Kuvan

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2008-12
Est. Completion 2011-07-19
Phase Phase 2

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT00841100

The ClinicalTrials.gov registry entry for NCT00841100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Diet is the first listed.

NCT00841100 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00841100 about?

NCT00841100 is a clinical study titled "Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response". The investigators will investigate the effect of blood phenylalanine on Kuvan responsiveness in the same patients with PKU when their blood phenylalanine concentrations are altered by diet. Lowering blood phenylalanine concentrations in Kuvan non-responsive patients with PKU will increase the frequ...

What is the current status of trial NCT00841100?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-12. Estimated completion is 2011-07-19.

What interventions are being tested in trial NCT00841100?

The interventions under investigation include: Diet (OTHER), Kuvan (DRUG).

Who is sponsoring clinical trial NCT00841100?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.